Navigation Links
SPO Secures Equity Line Facility of US$5 Million
Date:7/14/2011

NEW YORK, July 14, 2011 /PRNewswire/ --


 

SPO (SPOM.OB), a leading developer of biosensor and microprocessor technologies for consumer wellness applications, today announced that it has entered into an Investment Agreement with Dutchess Opportunity Fund II, LP for a US$5 Million equity line facility.

Under the terms of the signed agreement, for a period of 36 months the Company has the option to sell and Dutchess the obligation to purchase common stock at a 6% discount to a calculated volume weighted average market price. In connection with establishing the equity line, the Company has agreed to file a registration statement with the U.S. Securities and Exchange Commission to register the resale by Dutchess of any shares issued to it under the equity line. Subject to the effectiveness of the registration statement and the satisfaction of other customary conditions, the Company may draw on the finance facility on a needed basis.

Michael Braunold, President and Chief Executive Officer of SPO commented, "We are pleased to enter into this financing agreement offering SPO a flexible infusion of cash with a well-established firm such as Dutchess. It is one of several financing strategies that will be pursued as we launch our innovative wellness products into the consumer mass-market environment. Dutchess has the track record and experience in the industry and has been a leader in providing equity lines for over 10 years which contributed significantly to selecting them as our partner."

Chris Quin, Vice President of Business Development of Dutchess, stated; "After reviewing the Company, we believe in Management's efforts to grow SPO and this facility provides inexpensive and flexible access capital. Regardless of the ever-tightening capital markets, we believe that SPO represents a compelling investment for our fund based on its exciting wellness product line. The line will allow Management the flexibility of raising capital
'/>"/>

SOURCE SPO Global
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology news :

1. Parente Randolph Secures Access to New Corporate Headquarters With BIO-key(R) Biometric Identification
2. National Institutes of Health Secures Armory with Patent-Pending Technology
3. NextCAT Inc. secures $250,000 to commercialize biodiesel technology developed at Wayne State
4. NextCAT secures license agreement for advanced biofuel technology from Wayne State
5. Equity concerns raised by congestion pricing can be addressed to make approach viable
6. Molecular Biometrics Closes $12.5 Million Series B Equity Funding
7. S&P Equity Research; Health Care Reform After The Buzzsaw - Where Are We Now?
8. First fuel-handling facility in the Galapagos earns environmental certification
9. Plankton Power and RTDC announce proposed algae-to-biofuels pilot facility on Cape Cod
10. NSF grant to launch worlds first open-source genetic parts production facility
11. University of Miami facility awarded prestigious LEED Green Building Certification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... by Northwestern Medicine® scientists helps explain how bipolar disorder ... new drug therapies to treat the mental illness. ... the same method recognized with the 2014 Nobel ... brain tissue from mice with bipolar-like behaviors. In the ... tiny "nanodomain" structures with concentrated levels of ANK3 -- ...
(Date:10/18/2014)... and stress-related psychiatric disorders are associated with ... molecular mechanisms underlying this relation are unknown. ... development of targeted preventive strategies and new ... This work is presented at the European ... an international group of researchers from Germany ...
(Date:10/17/2014)... Copenhagen have shown for the first time how bacteria ... patients, giving them the opportunity to get tremendous insights ... The study also discovered the bacterial growth in chronic ... or slowed down by the immune cells. The researchers ... helped "suffocate" the bacteria, forcing the bacteria to switch ...
Breaking Biology News(10 mins):Bipolar disorder discovery at the nano level 2Researchers find why depression and aging linked to increased disease risk 2Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2
... daily recommended dosages of ibuprofen and acetaminophen caused a ... quadriceps muscle mass and muscle strength gained during three ... physiologists at the Human Performance Laboratory, Ball State University. ... working with Dr. Todd Trappe, reported study results at ...
... Laboratory will host the inaugural conference of the ... create a virtual center in cyberspace for plant ... "Bringing Plant and Computing Scientists Together to Solve ... 7-9, 2008, will take the first steps in ...
... As the saying goes, some people are born with ... at least one species of the animal world, according ... Alberta. A study of female red squirrels in ... as food availability and spring temperature experienced between birth ...
Cached Biology News:Ibuprofen or acetaminophen in long-term resistance training increases muscle mass/strength 2iPlant Kickoff Conference at CSHL begins tackling plant biology's grand challenges 2iPlant Kickoff Conference at CSHL begins tackling plant biology's grand challenges 3
(Date:10/25/2014)... 24, 2014 This research report ... Starch Based Plastics, Regenerated Cellulose, PCL), by Application ... and Forecasts to 2019”, defines and segments the ... forecast of its global volume and value. , ... spread through 178 Slides and in-depth TOC on ...
(Date:10/25/2014)... SonaCare Medical, LLC, leader in ... announced that its Board of Directors has appointed ... President and member of the Board effective immediately. ... expanded responsibilities within the company, including further developing ... commercialization, manufacturing and finance. , Dr. Carol ...
(Date:10/25/2014)... Great Barrington, MA (PRWEB) October 25, 2014 ... contamination control products, is pleased to announce the ... to achieve the highest level of contamination containment ... in ISO Class 3 and higher cleanroom environments, ... continuous filament polyester knit laundered wiper that continues ...
(Date:10/25/2014)... NEW YORK , Oct. 24, 2014 ... Access Pharmaceuticals, Inc. (ACCP), a biopharmaceutical company advancing ... implemented a 1-for-50 reverse split of its common ... Friday, October 24, 2014. PlasmaTech,s common stock will ... number 72754H109 and temporary ticker symbol "ACCPD". After ...
Breaking Biology Technology:Biodegradable Plastics Market Projected to $3,476.87 Million by 2019 - Report by MarketsandMarkets 2Biodegradable Plastics Market Projected to $3,476.87 Million by 2019 - Report by MarketsandMarkets 3Biodegradable Plastics Market Projected to $3,476.87 Million by 2019 - Report by MarketsandMarkets 4SonaCare Medical Board of Directors Appoints Dr. Mark Carol as CEO and President 2SonaCare Medical Board of Directors Appoints Dr. Mark Carol as CEO and President 3Ions Are Bygones, Berkshire Announces the Release of New Innovative Cleanroom Wipers 2PlasmaTech Biopharmaceuticals, Inc. Announces Reverse Stock Split, Ticker Change and Launches New Corporate Website 2
... April 8 ImQuest Life Sciences presented their ... their novel small molecule piperazine compound for the ... Therapeutics meeting held in Whistler, British Columbia. The ... lead microtubule inhibitor, IQP-0304. The piperazines demonstrate potent ...
... 8 Micromet, Inc. (Nasdaq: MITI ... for the treatment of cancer, inflammation and autoimmune ... the peer-reviewed Journal of Immunotherapy (1) demonstrating the ... to carcinoembryonic antigen (CEA) and to CD3 on ...
... 7 Pharmatech Oncology, Inc., a Research Management Organization ... companies at the Company Showcase during BIOZONA 2009 - ... Downtown on April 7th in Phoenix, Arizona.Matthew B. Wiener, ... during the first session of the conference. The ...
Cached Biology Technology:ImQuest Presentation at Keystone Symposium Focuses on Advancements in Their Cancer Research and Development Program 2Pre-Clinical Data on CEA-specific BiTE Antibody Published in Journal of Immunotherapy Demonstrate Potent Control of Tumor Growth 2Pre-Clinical Data on CEA-specific BiTE Antibody Published in Journal of Immunotherapy Demonstrate Potent Control of Tumor Growth 3Pre-Clinical Data on CEA-specific BiTE Antibody Published in Journal of Immunotherapy Demonstrate Potent Control of Tumor Growth 4Pharmatech Oncology Selected to Present at Company Showcase at BIOZONA 2
MAb to Vasopressin Preservative: NaN3...
... Anti-AP-2 α, clone 8G8/5 GenBank Accession ... made human AP-2alpha/gamma fusion protein corresponding to ... 278-450 of human AP-2γ Formulation: 0.1M Tris-glycine, ... before the addition of glycerol to 30% ...
Mouse monoclonal [1C6/2] to Rad17 ( Abpromise for all tested applications). entrezGeneID: 5884 SwissProtID: Q9UPF5...
MMP-2 / MMP-9 Inhibitor IV is a potent, selective, slow binding and mechanism based inhibitor of human gelatinases. • Molecular weight: 306.4 • Molecular Formula: C(15)H(14)O(3)S(2). &bul...
Biology Products: